-+ 0.00%
-+ 0.00%
-+ 0.00%

Aclaris Begins Phase 2b Modzatinib Trial In Lichen Planus, Fast Track-Designated Dual ITK/JAK3 Inhibitor With Potential As First Mechanistically Complete Oral Therapy

Benzinga·11/16/2026 08:35:49
Listen to the news

- Dual Inhibition of ITK and JAK3 Provides Potential for Modzatinib to be the First Mechanistically Complete Oral Therapy for Lichen Planus, an Unaddressed Inflammatory Disease with No Approved Therapeutic Options -

- Unique Mechanism Targets Key Pathways Implicated in LP Pathology, T-cell Receptor Signaling Upstream and Effector Cytokine Signaling Downstream -